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The goal of the Work Group was to develop performance measures based on processes, structures, and outcomes to achieve high-quality care. Desired outcomes for breast reconstruction patients include reduction of reoperations and revision operations, reduction of complications, identification and reduction of barriers in access to care, encouragement of a multispecialty approach to breast reconstruction, promotion of shared decision-making, and continuous improvement in quality of life.
Scope and Intended Users
The American Society of Plastic Surgeons encourages the use of these measures by plastic surgeons and other health care professionals. These performance measures can be implemented into quality improvement, Continuing Medical Education, Maintenance of Certification, and national quality reporting programs to facilitate practitionerand system-level quality improvement. Ultimately, the use of these measures should support better outcomes for breast reconstruction patients. These draft measures have been designated for accountability, as they are intended to be tested for scientific acceptability.
Diversity of Breast Reconstruction Outcomes Literature
Breast reconstruction after mastectomy encompasses a diverse range of surgical techniques: autologous free or pedicled tissue transfer of fasciocutaneous or musculofasciocutaneous flaps from a variety of donor sites including the abdomen, back, and legs; autologous fat grafting in series; and silicone or saline internal prostheses, with all of these techniques able to be considered in immediate, staged with tissue expander, or delayed fashion. Further diversity is introduced into the field by consideration of unilateral versus bilateral reconstructions, revision operations, possible use of acellular dermal matrix products and different implant types, varied neoadjuvant and adjuvant oncology treatments, and mastectomy techniques such as nipple-sparing procedures. Outcomes may be assessed on diverse aspects such as preoperative workup and decision-making, associated costs, appearance, function, absence of complications, and patient report of satisfaction.
Studies generally support the importance of breast reconstruction after mastectomy. Atisha et al. demonstrated through patient-reported outcomes that women who underwent autologous tissue reconstruction reported the highest breast satisfaction, whereas women undergoing mastectomy without reconstruction reported the lowest satisfaction. 2 Alderman et al., among others, suggest that women who underwent immediate reconstruction were significantly more satisfied with their surgical treatment decision compared with those who underwent mastectomy only. 3 Other literature demonstrates that women who underwent mastectomy with reconstruction reported better quality of life compared with women who underwent mastectomy only. These outcomes included higher satisfaction with breasts, psychosocial wellbeing, and sexual well-being. 4 Beyond the fairly robust and consistent body of literature supporting the validity of breast reconstruction in general, the diversity of the field is revealed through the diversity of outcomes reported. Even a review of the most recent literature characterizes the difficulty of standardization of expectations in breast reconstruction. Wade et al. have noted that bilateral deep inferior epigastric perforator flaps have higher rates of complications and flap failure compared with unilateral reconstructions in their series of over 500 flaps. 5 Several studies have demonstrated differences in reconstruction rates and choices of reconstruction types between races and ethnicities. 6, 7 Berlin et al. have demonstrated racial and ethnic variations in clinical and patient-reported outcomes in breast reconstruction. 8 Pittman et al., among others, have demonstrated differences in clinical outcomes and complications with use of different types of acellular dermal matrices. 9, 10 There is no clear consensus on the risk level associated with the use of acellular dermal matrix. 11 Pirro et al. show differences in patient satisfaction with different types of reconstruction. 12 Regarding timing, Susarla et with higher sexual well-being and satisfaction, it is more likely to require additional operative revisions compared with two-stage prosthetic-based reconstruction. 13 Complications and increased patient age at the time of reconstruction may decrease satisfaction. Furthermore, patients with a prophylactic mastectomy are more likely than those with a therapeutic mastectomy to be dissatisfied when complications arise.
14 The body of literature is vast documenting potential differences in expectations based on the specific details of each reconstruction.
METHODS
American Society of Plastic Surgeons members were invited to apply to the Work Group by means of Society e-mail and fax communication. All applicants were required to submit an online conflict-of-interest disclosure form for membership consideration. Members of the American Society of Plastic Surgeons Quality and Performance Measurement Committee reviewed and selected Work Group members to ensure a diverse representation of U.S. regions, practice type (i.e., large multispecialty group practice, small group practice, solo practice, and academic practice), experience in clinical research, and evidence-based medicine expertise. Five stakeholder organizations, including the American Society of Breast Surgeons, the American College of Radiology, the American Society of Clinical Oncology, Susan G. Komen for the Cure, and the American Board of Plastic Surgery were also invited to participate in the measure-development process. Each organization nominated one member from their respective organization to serve on the Work Group.
The technical specifications drafted for this performance measurement set were drafted as registry specifications, because many American Society of Plastic Surgeons members are in solo and small group practices and have not yet implemented electronic health records. Electronic health record specifications may be added after confirmation of the inclusion of these measures.
For performance measure exceptions, the American Society of Plastic Surgeons uses the American Medical Association Physician Consortium for Performance Improvement exception criteria, which are divided by medical, patient, and system reasons. 15 
Other Potential Measures
The Breast Reconstruction Performance Measure Development Work Group considered developing several additional measures for this patient population. The draft measures that were not fully developed are included below.
Capsular Contracture
This measure was originally in the draft measures document. It measured rates of capsular contracture in breast reconstruction by means of expander or implant in patients who present with capsular contracture for which medical and/ or surgical intervention is recommended within 12 months of the primary breast reconstruction procedure. The measure was removed from this current measure set because there is not clear evidence that providers can prevent capsular contracture.
Shared Decision-Making
This draft measure focused on informing patients of specific risks and was excluded because a discussion of risks and benefits would be included in the informed consent process.
Care Coordination
The care coordination measure would have focused on highlighting the importance of a multidisciplinary team coordinating patient care. The Work Group came to consensus that this would be an alternate measure if one of the prioritized measures was not feasible.
Risk Assessment
The Work Group was unable to achieve consensus on a validated risk assessment tool to be used in this measure.
Reconstruction Options
This draft measure would have focused on promoting access to care in the rural environment. This would have been operationalized by using zip codes. The draft measure could not be created because data collection was not feasible.
Treatment Planning
This measure would have encouraged operations to be completed in a specific amount of time, but Work Group members did not reach consensus on an optimal surgical time.
Direct-to-Implant Reconstruction
The Work Group concluded that direct-toimplant reconstruction is not always appropriate and there is a question of how large the gap in care may be.
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Functional Status
The Work Group was unable to achieve consensus on a validated functional status tool to be used in this measure.
Cost of Care
Staff referred the Work Group to the recently endorsed National Quality Forum Cost Measure and suggested not creating a new cost measure unless it could be harmonized.
Clinical Evidence Base
Performance 20 Therefore, the population chosen for the measure is sizable.
Complications requiring return to the operating room were chosen as an outcomes measure based on the presumed burden when these occur. For example, one type of complication, surgical-site infection, contributes to extended hospital stays and increased health care costs. In addition, surgical-site infections can compromise the outcome of reconstruction and may result in decreased patient satisfaction. 21 The infection rates in implant-based reconstruction vary from 5.1 to 28 percent. Risk factors for infection include the following: presence of cellulitis, inpatient procedures, irradiation, contralateral breast surgery, breast size, tobacco use, obesity, patient age older than 65 years, and the use of acellular dermal matrix. Clinical manifestations of infection include erythema, swelling, fever, and the presence of pathogens through periprosthetic culturing. 22 The measure was designed to more globally encompass potential complications known to occur after breast reconstruction, rather than to focus solely on any one type of complication. The following defines complications in the referenced clinical guideline recommendation: "Complications, although not limited to, most commonly include the following: infection, hematoma, seroma, wound dehiscence, skin flap necrosis, expander/implant loss, malposition, expander/implant deflation, capsular contraction, hypertrophic or keloid scarring, and venous thromboembolism disease" (Level II Evidence, Recommendation Grade: B).
Given current limitations in defining, tracking, and recording mild manifestations of complications, the measure was defined to include complications requiring return to the operating room. The complexity of tracking and attributing complications is summarized in the following statement, taken verbatim from the referenced clinical guideline recommendation: "Evidence is varied and conflicting on the association between postoperative complications and the timing of postmastectomy expander/implant breast reconstruction and is often confounded by the use of radiation. The inconsistent research findings and a lack of evidence should alert physicians to evaluate each case individually" (Level II, III, IV Evidence, Recommendation Grade: C). 16 Therefore, effort was directed toward development of clear measure language that would be able to be consistently understood and used.
Breast Reconstruction: Flap Loss
Description This group consisted of female patients aged 18 years and older who underwent breast reconstruction by means of autologous reconstruction (not including latissimus flap) with or without a 19357, 19357-50, 19340, 19340-50,19342, 19342-50, 19361, 19361-50, 19364, 19364-50, 19367, 19367-50, 19368, 19368-50, 19369, 19369- 20 Therefore, the population chosen for the measure is sizable.
Flap loss is well-established as a significant complication endpoint. In general, rates are low, but the morbidity associated with this complication is high. A variety of literature explores potential factors that may impact this. Myriad factors have been assessed for impact on flap viability, and a few include unilateral versus bilateral reconstructions, 5 tamoxifen use, 23 operative factors such as blood loss and length of surgery, 24 and flap characteristics. 25, 26 However, much accepted variability in practice exists, as consistent findings with high levels of evidence are rare.
The 30-day time point was chosen based on the generally held belief among Work Group members that nonviable tissue occurring as a result of the flap surgery would fully manifest within 30 days postoperatively. Flap loss has been left to the practitioner to define, as data are lacking regarding clinical significance associated with percentages of nonviable transferred tissue. It is hoped that use of this measure over time will facilitate data collection and analysis that may continue the current literature trends that attempt to improve recommendations that can guide physicians in practice choices that may improve outcomes. 
